TY - JOUR
T1 - The Safety of Adiponectin Receptor Agonist AdipoRon in a Rabbit Model of Arthrofibrosis
AU - Salmons, Harold I.
AU - Gow, Christopher
AU - Limberg, Afton K.
AU - Bettencourt, Jacob W.
AU - Carstens, Mason F.
AU - Payne, Ashley N.
AU - Morrey, Mark E.
AU - Sanchez-Sotelo, Joaquin
AU - Berry, Daniel J.
AU - Dudakovic, Amel
AU - Abdel, Matthew P.
N1 - Funding Information:
This study was pursued with the generous philanthropic support of Anna-Maria and Stephen Kellen Foundation (to M.P.A.). This study was also supported in part by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under award number R01 AR072597 (to M.P.A.) and Regenerative Medicine Minnesota under award number RMM 091620 TR 010 (to M.P.A.). D.J.B. is funded by grants from the National Institutes of Health (R01AR73147, R01HL147155), NIAMS (P30AR76312).
Funding Information:
This study was pursued with the generous philanthropic support of Anna-Maria and Stephen Kellen Foundation (to M.P.A.). This study was also supported in part by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under award number R01 AR072597 (to M.P.A.).
Publisher Copyright:
© 2023 Mary Ann Liebert, Inc.
PY - 2023/4/1
Y1 - 2023/4/1
N2 - AdipoRon is an adiponectin receptor 1, 2 (ADIPOR1 and ADIPOR2) agonist with numerous reported physiological benefits in murine models of human disease, including a proposed reduction in fibrosis. However, AdipoRon has never been investigated in rabbits, which provide a robust model for orthopedic conditions. We examined the safety of intravenous (IV) AdipoRon in New Zealand White (NZW) female rabbits surgically stressed by a procedure that mimics human arthrofibrosis. Fifteen female NZW rabbits were prospectively studied using increasing AdipoRon doses based on established literature. AdipoRon was dissolved in dimethyl sulfoxide (DMSO), diluted in normal saline, and administered IV preoperatively and for 5 subsequent days postoperatively. The primary outcome was overall toxicity to rabbits, whereas secondary outcomes were change in rabbit weights and hemodynamics and defining acid-base characteristics of the drug formulation. Two rabbits expired during preoperative drug administration at 25 mg/kg. Remaining rabbits received preoperative doses of DMSO (vehicle), 2.5, 5, or 10 mg/kg of AdipoRon without complications. On postoperative day 1, one rabbit sustained a tonic-clonic seizure after their second dose of 10 mg/kg AdipoRon. The remaining 12 rabbits (4 in each group) received six serial doses of vehicle, 2.5, or 5 mg/kg of AdipoRon without adverse effects. All formulations of AdipoRon were within safe physiological pH ranges (4-5). We are the first to report the use of IV AdipoRon in a surgically stressed rabbit model of orthopedic disease. AdipoRon doses of 5 mg/kg or less appear to be well-tolerated in female NZW rabbits. We provided the first in vivo toxicity assessment and dose optimization of a new antifibrotic experimental medication, AdipoRon, in a surgically stressed rabbit model of knee arthrofibrosis.
AB - AdipoRon is an adiponectin receptor 1, 2 (ADIPOR1 and ADIPOR2) agonist with numerous reported physiological benefits in murine models of human disease, including a proposed reduction in fibrosis. However, AdipoRon has never been investigated in rabbits, which provide a robust model for orthopedic conditions. We examined the safety of intravenous (IV) AdipoRon in New Zealand White (NZW) female rabbits surgically stressed by a procedure that mimics human arthrofibrosis. Fifteen female NZW rabbits were prospectively studied using increasing AdipoRon doses based on established literature. AdipoRon was dissolved in dimethyl sulfoxide (DMSO), diluted in normal saline, and administered IV preoperatively and for 5 subsequent days postoperatively. The primary outcome was overall toxicity to rabbits, whereas secondary outcomes were change in rabbit weights and hemodynamics and defining acid-base characteristics of the drug formulation. Two rabbits expired during preoperative drug administration at 25 mg/kg. Remaining rabbits received preoperative doses of DMSO (vehicle), 2.5, 5, or 10 mg/kg of AdipoRon without complications. On postoperative day 1, one rabbit sustained a tonic-clonic seizure after their second dose of 10 mg/kg AdipoRon. The remaining 12 rabbits (4 in each group) received six serial doses of vehicle, 2.5, or 5 mg/kg of AdipoRon without adverse effects. All formulations of AdipoRon were within safe physiological pH ranges (4-5). We are the first to report the use of IV AdipoRon in a surgically stressed rabbit model of orthopedic disease. AdipoRon doses of 5 mg/kg or less appear to be well-tolerated in female NZW rabbits. We provided the first in vivo toxicity assessment and dose optimization of a new antifibrotic experimental medication, AdipoRon, in a surgically stressed rabbit model of knee arthrofibrosis.
KW - adiponectin
KW - arthrofibrosis
KW - intravenous
KW - knee
KW - toxicity
UR - http://www.scopus.com/inward/record.url?scp=85152616489&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85152616489&partnerID=8YFLogxK
U2 - 10.1089/ten.tec.2023.0008
DO - 10.1089/ten.tec.2023.0008
M3 - Article
C2 - 36924279
AN - SCOPUS:85152616489
SN - 1937-3384
VL - 29
SP - 154
EP - 159
JO - Tissue Engineering - Part C: Methods
JF - Tissue Engineering - Part C: Methods
IS - 4
ER -